National Health Investors vs Sabra Health Care REIT
NHI and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NHI and SBRA compare
Sabra Health Care REIT is the larger company, worth 1.8 times as much as National Health Investors ($5.2B against $2.9B).
On earnings, National Health Investors is cheaper: it trades at 17.3× trailing earnings, against 77.9× for Sabra Health Care REIT.
National Health Investors grew revenue faster over the last twelve months (23.9% versus 17.3% for Sabra Health Care REIT).
National Health Investors keeps more of each dollar of sales as profit, with a net margin of 38.6% compared with 7.6% at Sabra Health Care REIT.
Both pay dividends: National Health Investors yields 6.2% and Sabra Health Care REIT 5.9%.
National Health Investors scores higher on the StockData Score (14 against 6 for Sabra Health Care REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NHI | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $2.9B | $5.2B |
| Share price | $59.98 | $20.25 |
| Change, 1 year | −22.3% | 8.6% |
| Change, 5 years | 13.7% | 53.3% |
| Beta (5Y) | −0.49 | −0.08 |
| Employees | 32 | 58 |
| StockData Score | ||
| Total score | 14 (better) | 6 |
| Valuation score | 3 (better) | 0 |
| Growth score | 5 (better) | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 0 | 0 |
| Dividend score | 3 | 3 |
| Valuation | ||
| P/E | 17.3× (better) | 77.9× |
| P/S | 6.8× | 6.0× (better) |
| P/B | 1.9× (better) | 1.9× |
| EV/EBITDA | – | 12.8× |
| PEG | 0.65 | – |
| Fair value | $70.31 | $12.75 |
| Margin of safety | 14.7% (better) | −58.8% |
| Growth | ||
| Revenue growth (TTM) | 23.9% (better) | 17.3% |
| Revenue growth, 5Y average | 2.5% | 5.3% (better) |
| Net income growth (TTM) | 16.7% (better) | −64.1% |
| EPS growth (TTM) | 10.5% (better) | −65.8% |
| EPS growth, 5Y average | −6.1% | −0.91% (better) |
| Profitability | ||
| Net margin | 38.6% (better) | 7.6% |
| Return on equity | 10.9% (better) | 2.4% |
| Financial health | ||
| Altman Z-score | 2.77 (better) | 1.28 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Dividend yield | 6.2% (better) | 5.9% |
| Payout ratio | 105% | 455% |
| Years of dividend growth | 1 (better) | 0 |
| Dividend growth, 5Y average | −4.6% | −2.3% (better) |
| Buyback yield | −3.5% | – |
| Shareholder yield | 2.7% | 5.9% (better) |
| Ownership | ||
| Held by institutions | 77.7% | 102% |
| Held by insiders | 2.5% | 1.9% |
| Insider net buying, 12 months | $167K (better) | −$4.7M |
| Short interest, % of float | 4.6% | 7.1% |
Go deeper
- NHI stock overview
- NHI income statement
- NHI valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.